The therapy joins another VMAT2 inhibitor, NBI-1065890, which is undergoing assessment by the company in Phase I trials.

TD, or tardive dyskinesia, is pretty much uncontrollable, jerky movements of the body. Smacking of the lips, licking, or jaw movements. I have Tourette's, and I kind of feel like it's just an ...

Tardive dyskinesia can affect many areas of your life, including your social life and self-confidence. Learning how to manage these effects can help improve your overall well-being and daily ...

Biosciences announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and ...

Let’s discuss how Tardive Dyskinesia (TD) affects your life and what you can do to overcome these difficulties.

The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The condition is characterised by uncontrollable movement of the body or ...

The company noted that the KINECT-PRO is the first study to show patient-reported impact of a vesicular monoamine transporter 2 inhibitor, specifically INGREZZA, on tardive dyskinesia or TD using ...

Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that ...

Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained ...